Viral pathogen-associated molecular patterns regulate blood-brain barrier integrity via competing innate cytokine signals

mBio

Volumn 5, Issue 5, 2014, Pages

  Daniels, Brian P ^a   Holman, David W ^a   Cruz Orengo, Lillian ^a   Jujjavarapu, Harsha ^a   Durrant, Douglas M ^a   Klein, Robyn S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PATTERN RECOGNITION RECEPTOR; RAC1 PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; CYTOKINE; NEUROPEPTIDE; RAC1 PROTEIN, MOUSE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; CYTOKINE RESPONSE; ENZYME ACTIVATION; FLAVIVIRUS INFECTION; IN VIVO STUDY; INNATE IMMUNITY; INTRACELLULAR TRANSPORT; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TIGHT JUNCTION; VIRUS CELL INTERACTION; WEST NILE FLAVIVIRUS; ANIMAL; BRAIN; C57BL MOUSE; CENTRAL NERVOUS SYSTEM; CYTOLOGY; DISEASE MODEL; ENDOTHELIUM CELL; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY; VIROLOGY; VIRUS REPLICATION; WEST NILE FEVER; WEST NILE VIRUS;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM; CYTOKINES; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; HOST-PATHOGEN INTERACTIONS; IMMUNITY, INNATE; INTERFERON TYPE I; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROPEPTIDES; RAC1 GTP-BINDING PROTEIN; RECEPTORS, PATTERN RECOGNITION; RHO GTP-BINDING PROTEINS; TIGHT JUNCTIONS; VIRUS REPLICATION; WEST NILE FEVER; WEST NILE VIRUS;

EID: 84908428514     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01476-14     Document Type: Article

References (68)

1. Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. 2006. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J. Neuroimmune Pharmacol. 1:223-236. http:// dx.doi.org/10.1007/s11481-006-9025-3.
2. Verma S, Lo Y, Chapagain M, Lum S, Kumar M, Gurjav U, Luo H, Nakatsuka A, Nerurkar VR. 2009. West Nile virus infection modulates human brain microvascular endothelial cells tight junction proteins and cell adhesion molecules: transmigration across the in vitro blood-brain barrier. Virology 385:425- 433. http://dx.doi.org/10.1016/ j.virol.2008.11.047.
3. Daffis S, Samuel MA, Suthar MS, Gale M, Jr, Diamond MS. 2008. Toll-like receptor 3 has a protective role against West Nile virus infection. J. Virol. 82:10349-10358. http://dx.doi.org/10.1128/JVI.00935-08.
4. Wang S, Welte T, McGargill M, Town T, Thompson J, Anderson JF, Flavell RA, Fikrig E, Hedrick SM, Wang T. 2008. Drak2 contributes to West Nile virus entry into the brain and lethal encephalitis. J. Immunol. 181:2084-2091. http://dx.doi.org/10.4049/jimmunol.181.3.2084.
5. Pan W, Stone KP, Hsuchou H, Manda VK, Zhang Y, Kastin AJ. 2011. Cytokine signaling modulates blood-brain barrier function. Curr. Pharm. Des. 17:3729-3740. http://dx.doi.org/10.2174/138161211798220918.
6. Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E, Flavell RA. 2004. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat. Med. 10:1366-1373. http://dx.doi.org/ 10.1038/nm1140.
7. Carson PJ, Konewko P, Wold KS, Mariani P, Goli S, Bergloff P, Crosby RD. 2006. Long-term clinical and neuropsychological outcomes of West Nile virus infection. Clin. Infect. Dis. 43:723-730. http://dx.doi.org/ 10.1086/506939.
8. Benedict CA. 2003. Viruses and the TNF-related cytokines, an evolving battle. Cytokine Growth Factor Rev. 14:349 -357. http://dx.doi.org/ 10.1016/S1359-6101(03)00030-3.
9. Stokes CA, Ismail S, Dick EP, Bennett JA, Johnston SL, Edwards MR, Sabroe I, Parker LC. 2011. Role of interleukin-1 and MyD88-dependent signaling in rhinovirus infection. J. Virol. 85:7912-7921. http:// dx.doi.org/10.1128/JVI.02649-10.
10. Shrestha B, Zhang B, Purtha WE, Klein RS, Diamond MS. 2008. Tumor necrosis factor alpha protects against lethal West Nile virus infection by promoting trafficking of mononuclear leukocytes into the central nervous system. J. Virol. 82:8956-8964. http://dx.doi.org/10.1128/JVI.01118-08.
11. Zhang B, Patel J, Croyle M, Diamond MS, Klein RS. 2010. TNF-alphadependent regulation of CXCR3 expression modulates neuronal survival during West Nile virus encephalitis. J. Neuroimmunol. 224:28-38. http:// dx.doi.org/10.1016/j.jneuroim.2010.05.003.
12. Ramos HJ, Lanteri MC, Blahnik G, Negash A, Suthar MS, Brassil MM, Sodhi K, Treuting PM, Busch MP, Norris PJ, Gale M, Jr. 2012. IL-1beta signaling promotes CNS-intrinsic immune control of West Nile virus infection. PLoS Pathog. 8(11):e1003039. http://dx.doi.org/10.1371/ journal.ppat.1003039.
13. Durrant DM, Robinette ML, Klein RS. 2013. IL-1R1 is required for dendritic cell-mediated T cell reactivation within the CNS during West Nile virus encephalitis. J. Exp. Med. 210:503-516. http://dx.doi.org/ 10.1084/jem.20121897.
14. Chai Q, He WQ, Zhou M, Lu H, Fu ZF. 2014. Enhancement of bloodbrain barrier permeability and reduction of tight junction protein expression are modulated by chemokines/cytokines induced by rabies virus infection. J. Virol. 88:4698-4710. http://dx.doi.org/10.1128/JVI.03149-13.
15. Platanias LC. 2005. Mechanisms of type-I- and type-II-interferonmediated signalling. Nat. Rev. Immunol. 5:375-386. http://dx.doi.org/ 10.1038/nri1604.
16. Samuel MA, Diamond MS. 2005. Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J. Virol. 79:13350 -13361. http://dx.doi.org/ 10.1128/JVI.79.21.13350-13361.2005.
17. _T cell maturation during acute West Nile virus infection. PLoS Pathog. 7(12):e1002407. http://dx.doi.org/ 10.1371/journal.ppat.1002407.
18. Lazear HM, Pinto AK, Vogt MR, Gale M, Jr, Diamond MS. 2011. Beta interferon controls West Nile virus infection and pathogenesis in mice. J. Virol. 85:7186-7194. http://dx.doi.org/10.1128/JVI.00396-11.
19. Lazear HM, Lancaster A, Wilkins C, Suthar MS, Huang A, Vick SC, Clepper L, Thackray L, Brassil MM, Virgin HW, Nikolich-Zugich J, Moses AV, Gale M, Fruh K, Diamond MS. 2013. IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. PLoS Pathog. 9(1):e1003118. http:// dx.doi.org/10.1371/journal.ppat.1003118.
20. Kraus J, Oschmann P. 2006. The impact of interferon-beta treatment on the blood-brain barrier. Drug Discov. Today 11:755-762. http:// dx.doi.org/10.1016/j.drudis.2006.06.008.
21. Markowitz CE. 2007. Interferon-beta: mechanism of action and dosing issues. Neurology 68:S8 -11. http://dx.doi.org/10.1212/ 01.wnl.0000256345.01907.09.
22. McCandless EE, Zhang B, Diamond MS, Klein RS. 2008. CXCR4 antagonism increases T cell trafficking in the central nervous system and improves survival from West Nile virus encephalitis. Proc. Natl. Acad. Sci. U. S. A. 105:11270-11275. http://dx.doi.org/10.1073/pnas.0800898105.
23. Engle MJ, Diamond MS. 2003. Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J. Virol. 77:12941-12949. http://dx.doi.org/10.1128/JVI.77.24.12941-12949.2003.
24. Busch MP, Kleinman SH, Tobler LH, Kamel HT, Norris PJ, Walsh I, Matud JL, Prince HE, Lanciotti RS, Wright DJ, Linnen JM, Caglioti S. 2008. Virus and antibody dynamics in acute west Nile virus infection. J. Infect. Dis. 198:984-993. http://dx.doi.org/10.1086/591467.
25. Chu JJ, Ng ML. 2003. The mechanism of cell death during West Nile virus infection is dependent on initial infectious dose. J. Gen. Virol. 84: 3305-3314. http://dx.doi.org/10.1099/vir.0.19447-0.
26. Etienne-Manneville S, Hall A. 2002. Rho GTPases in cell biology. Nature 420:629-635. http://dx.doi.org/10.1038/nature01148.
27. Szretter KJ, Daffis S, Patel J, Suthar MS, Klein RS, Gale M, Jr, Diamond MS. 2010. The innate immune adaptor molecule MyD88 restricts West Nile virus replication and spread in neurons of the central nervous system. J. Virol. 84:12125-12138. http://dx.doi.org/10.1128/JVI.01026-10.
28. Pinto AK, Ramos HJ, Wu X, Aggarwal S, Shrestha B, Gorman M, Kim KY, Suthar MS, Atkinson JP, Gale M, Jr, Diamond MS. 2014. Deficient IFN signaling by myeloid cells leads to MAVS-dependent virus-induced sepsis. PLoS Pathog. 10(4):e1004086. http://dx.doi.org/10.1371/ journal.ppat.1004086.
29. Daffis S, Samuel MA, Suthar MS, Keller BC, Gale M, Diamond MS. 2008. Interferon regulatory factor IRF-7 induces the antiviral alpha interferon response and protects against lethal West Nile virus infection. J. Virol. 82:8465-8475. http://dx.doi.org/10.1128/JVI.00918-08.
30. Tsao N, Hsu HP, Wu CM, Liu CC, Lei HY. 2001. Tumour necrosis factor-alpha causes an increase in blood-brain barrier permeability during sepsis. J. Med. Microbiol. 50:812-821.
31. Wong D, Dorovini-Zis K, Vincent SR. 2004. Cytokines, nitric oxide, and cGMP modulate the permeability of an in vitro model of the human blood-brain barrier. Exp. Neurol. 190:446 - 455. http://dx.doi.org/ 10.1016/j.expneurol.2004.08.008.
32. Phares TW, Kean RB, Mikheeva T, Hooper DC. 2006. Regional differences in blood-brain barrier permeability changes and inflammation in the apathogenic clearance of virus from the central nervous system. J. Immunol. 176:7666 -7675. http://dx.doi.org/10.4049/ jimmunol.176.12.7666.
33. Forster C, Burek M, Romero IA, Weksler B, Couraud PO, Drenckhahn D. 2008. Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human blood-brain barrier. J. Physiol. 586:1937-1949. http://dx.doi.org/10.1113/jphysiol.2007.146852.
34. Minagar A, Long A, Ma T, Jackson TH, Kelley RE, Ostanin DV, Sasaki M, Warren AC, Jawahar A, Cappell B, Alexander JS. 2003. Interferon (IFN)-beta 1a and IFN-beta1b block IFN-gamma-induced disintegration of endothelial junction integrity and barrier. Endothelium 10:299-307. http://dx.doi.org/10.1080/714007544.
35. Patkar C, Giaya K, Libraty DH. 2013. Dengue virus type 2 modulates endothelial barrier function through CD73. Am. J. Trop. Med. Hyg. 88: 89-94. http://dx.doi.org/10.4269/ajtmh.2012.12-0474.
36. Kraus J, Ling AK, Hamm S, Voigt K, Oschmann P, Engelhardt B. 2004. Interferon-beta stabilizes barrier characteristics of brain endothelial cells in vitro. Ann. Neurol. 56:192-205. http://dx.doi.org/10.1002/ana.20161.
37. Guarda G, Braun M, Staehli F, Tardivel A, Mattmann C, Forster I, Farlik M, Decker T, Du Pasquier RA, Romero P, Tschopp J. 2011. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34:213-223. http://dx.doi.org/10.1016/ j.immuni.2011.02.006.
38. Huang Y, Blatt LM, Taylor MW. 1995. Type 1 interferon as an antiinflammatory agent: inhibition of lipopolysaccharide-induced interleukin- 1beta and induction of interleukin-1 receptor antagonist. J. Interferon Cytokine Res. 15:317-321. http://dx.doi.org/10.1089/jir.1995.15.317.
39. Argaw AT, Zhang Y, Snyder BJ, Zhao ML, Kopp N, Lee SC, Raine CS, Brosnan CF, John GR. 2006. IL-1beta regulates blood-brain barrier per- meability via reactivation of the hypoxia-angiogenesis program. J. Immunol. 177:5574-5584. http://dx.doi.org/10.4049/jimmunol.177.8.5574.
40. Blamire AM, Anthony DC, Rajagopalan B, Sibson NR, Perry VH, Styles P. 2000. Interleukin-1beta-induced changes in blood-brain barrier permeability, apparent diffusion coefficient, and cerebral blood volume in the rat brain: a magnetic resonance study. J. Neurosci. 20:8153-8159.
41. Roe K, Kumar M, Lum S, Orillo B, Nerurkar VR, Verma S. 2012. West Nile virus-induced disruption of the blood-brain barrier in mice is characterized by the degradation of the junctional complex proteins and increase in multiple matrix metalloproteinases. J. Gen. Virol. 93:1193-1203. http://dx.doi.org/10.1099/vir.0.040899-0.
42. Morrey JD, Olsen AL, Siddharthan V, Motter NE, Wang H, Taro BS, Chen D, Ruffner D, Hall JO. 2008. Increased blood-brain barrier permeability is not a primary determinant for lethality of West Nile virus infection in rodents. J. Gen. Virol. 89:467-473. http://dx.doi.org/10.1099/ vir.0.83345-0.
43. Dai J, Wang P, Bai F, Town T, Fikrig E. 2008. Icam-1 participates in the entry of west Nile virus into the central nervous system. J. Virol. 82: 4164-4168. http://dx.doi.org/10.1128/JVI.02621-07.
44. Arjona A, Foellmer HG, Town T, Leng L, McDonald C, Wang T, Wong SJ, Montgomery RR, Fikrig E, Bucala R. 2007. Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion. J. Clin. Invest. 117:3059 -3066. http:// dx.doi.org/10.1172/JCI32218.
45. Schafer A, Brooke CB, Whitmore AC, Johnston RE. 2011. The role of the blood-brain barrier during Venezuelan equine encephalitis virus infection. J. Virol. 85:10682-10690. http://dx.doi.org/10.1128/JVI.05032-11.
46. Glass WG, Lim JK, Cholera R, Pletnev AG, Gao JL, Murphy PM. 2005. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J. Exp. Med. 202:1087-1098. http://dx.doi.org/10.1084/jem.20042530.
47. _T-cell recruitment and control of West Nile virus encephalitis. J. Virol. 79:11457-11466. http://dx.doi.org/10.1128/JVI.79.17.11457-11466.2005.
48. _T cells in control of West Nile virus infection. J. Virol. 78:8312-8321. http://dx.doi.org/10.1128/ JVI.78.15.8312-8321.2004.
49. Lim JK, Obara CJ, Rivollier A, Pletnev AG, Kelsall BL, Murphy PM. 2011. Chemokine receptor Ccr2 is critical for monocyte accumulation and survival in West Nile virus encephalitis. J. Immunol. 186:471-478. http:// dx.doi.org/10.4049/jimmunol.1003003.
50. Town T, Bai F, Wang T, Kaplan AT, Qian F, Montgomery RR, Anderson JF, Flavell RA, Fikrig E. 2009. Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing. Immunity 30:242-253. http://dx.doi.org/10.1016/ j.immuni.2008.11.012.
51. _T cell-dependent clearance of West Nile virus from the central nervous system. J. Virol. 87:11401-11415. http://dx.doi.org/10.1128/ JVI.01403-13.
52. Diamond MS, Gale M, Jr. 2012. Cell-intrinsic innate immune control of West Nile virus infection. Trends Immunol. 33:522-530. http:// dx.doi.org/10.1016/j.it.2012.05.008.
53. Xia J, Winkelmann ER, Gorder SR, Mason PW, Milligan GN. 2013. TLR3- and MyD88-dependent signaling differentially influences the development of West Nile virus-specific B cell responses in mice following immunization with RepliVAX WN, a single-cycle flavivirus vaccine candidate. J. Virol. 87:12090 -12101. http://dx.doi.org/10.1128/JVI.01469- 13.
54. Wang P, Dai J, Bai F, Kong KF, Wong SJ, Montgomery RR, Madri JA, Fikrig E. 2008. Matrix metalloproteinase 9 facilitates West Nile virus entry into the brain. J. Virol. 82:8978 - 8985. http://dx.doi.org/10.1128/ JVI.00314-08.
55. Verma S, Kumar M, Gurjav U, Lum S, Nerurkar VR. 2010. Reversal of West Nile virus-induced blood-brain barrier disruption and tight junction proteins degradation by matrix metalloproteinases inhibitor. Virology 397:130-138. http://dx.doi.org/10.1016/j.virol.2009.10.036.
56. Persidsky Y, Heilman D, Haorah J, Zelivyanskaya M, Persidsky R, Weber GA, Shimokawa H, Kaibuchi K, Ikezu T. 2006. Rho-mediated regulation of tight junctions during monocyte migration across the bloodbrain barrier in HIV-1 encephalitis (HIVE). Blood 107:4770-4780. http:// dx.doi.org/10.1182/blood-2005-11-4721.
57. Gea-Banacloche J, Johnson RT, Bagic A, Butman JA, Murray PR, Agrawal AG. 2004. West Nile virus: pathogenesis and therapeutic options. Ann. Intern. Med. 140:545-553. http://dx.doi.org/10.7326/0003-4819- 140-7-200404060-00015.
58. Kalil AC, Devetten MP, Singh S, Lesiak B, Poage DP, Bargenquast K, Fayad P, Freifeld AG. 2005. Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases. Clin. Infect. Dis. 40:764-766. http:// dx.doi.org/10.1086/427945.
59. Winston DJ, Vikram HR, Rabe IB, Dhillon G, Mulligan D, Hong JC, Busuttil RW, Nowicki MJ, Mone T, Civen R, Tecle SA, Trivedi KK, Hocevar SN, Nile W, Virus Transplant-Associated Transmission Investigation Team. 2014. Donor-derived West Nile virus infection in solid organ transplant recipients: report of four additional cases and review of clinical, diagnostic, and therapeutic features. Transplantation 97: 881-889. http://dx.doi.org/10.1097/TP.0000000000000024.
60. Bigham AW, Buckingham KJ, Husain S, Emond MJ, Bofferding KM, Gildersleeve H, Rutherford A, Astakhova NM, Perelygin AA, Busch MP, Murray KO, Sejvar JJ, Green S, Kriesel J, Brinton MA, Bamshad M. 2011. Host genetic risk factors for West Nile virus infection and disease progression. PLoS One 6(9):e24745. http://dx.doi.org/10.1371/ journal.pone.0024745.
61. Lim JK, Lisco A, McDermott DH, Huynh L, Ward JM, Johnson B, Johnson H, Pape J, Foster GA, Krysztof D, Follmann D, Stramer SL, Margolis LB, Murphy PM. 2009. Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog. 5(2): e1000321. http://dx.doi.org/10.1371/journal.ppat.1000321.
62. Kong KF, Delroux K, Wang X, Qian F, Arjona A, Malawista SE, Fikrig E, Montgomery RR. 2008. Dysregulation of TLR3 impairs the innate immune response to West Nile virus in the elderly. J. Virol. 82:7613-7623. http://dx.doi.org/10.1128/JVI.00618-08.
63. Ebel GD, Dupuis AP, 2nd, Ngo K, Nicholas D, Kauffman E, Jones SA, Young D, Maffei J, Shi PY, Bernard K, Kramer LD. 2001. Partial genetic characterization of West Nile virus strains, New York State, 2000. Emerg. Infect. Dis. 7:650-653. http://dx.doi.org/10.3201/eid0704.017408.
64. Diamond MS, Shrestha B, Marri A, Mahan D, Engle M. 2003. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J. Virol. 77:2578-2586. http:// dx.doi.org/10.1128/JVI.77.4.2578-2586.2003.
65. Szretter KJ, Daniels BP, Cho H, Gainey MD, Yokoyama WM, Gale M, Jr, Virgin HW, Klein RS, Sen GC, Diamond MS. 2012. 2=-O methylation of the viral mRNA cap by West Nile virus evades ifit1-dependent and -independent mechanisms of host restriction in vivo. PLoS Pathog. 8(5): e1002698. http://dx.doi.org/10.1371/journal.ppat.1002698.
66. Patel JR, McCandless EE, Dorsey D, Klein RS. 2010. CXCR4 promotes differentiation of oligodendrocyte progenitors and remyelination. Proc. Natl. Acad. Sci. U. S. A. 107:11062-11067. http://dx.doi.org/10.1073/ pnas.1006301107.
67. Daniels BP, Cruz-Orengo L, Pasieka TJ, Couraud PO, Romero IA, Weksler B, Cooper JA, Doering TL, Klein RS. 2013. Immortalized human cerebral microvascular endothelial cells maintain the properties of primary cells in an in vitro model of immune migration across the blood brain barrier. J. Neurosci. Methods 212:173-179. http://dx.doi.org/ 10.1016/j.jneumeth.2012.10.001.
68. Cruz-Orengo L, Daniels BP, Dorsey D, Basak SA, Grajales-Reyes JG, McCandless EE, Piccio L, Schmidt RE, Cross AH, Crosby SD, Klein RS. 2014. Enhanced sphingosine-1-phosphate receptor 2 expression underlies female CNS autoimmunity susceptibility. J. Clin. Invest. 124:2571-2584. http://dx.doi.org/10.1172/JCI73408.